Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tipapkinogene sovacivec - Transgene

Drug Profile

Tipapkinogene sovacivec - Transgene

Alternative Names: MVA-HPV-IL2 vaccine; R-3484; RG 3484; RO5217790; TG 4001

Latest Information Update: 07 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Transgene
  • Developer EMD Serono Research & Development Institute; Merck & Co; Roche; Transgene
  • Class Cancer vaccines; Gene therapies; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Head and neck cancer; Oropharyngeal cancer
  • Discontinued Cervical cancer; Cervical intraepithelial neoplasia

Most Recent Events

  • 30 Sep 2019 Positive early efficacy data from a phase Ib/II trial in Head and neck cancer and Oropharyngeal cancer released by Transgene
  • 20 Dec 2018 Interim adverse events data from a phase I/II trial in Oropharyngeal cancer released by Transgene
  • 19 Sep 2017 Phase-I/II clinical trials in Oropharyngeal cancer (Combination therapy, Second-line therapy or greater) in France (SC) (NCT03260023)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top